Clinical trial
Sub-project of the Clinical Protocol ACH471-205 "An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471"
NCT03723512 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sub-project of the Clinical Protocol ACH471-205 "An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471"
- Lead sponsor
- Mario Negri Institute for Pharmacological Research
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 6, 2018
- Completion date
- February 17, 2021
- Enrollment
- 7 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
c3 glomerulonephritis, c3 glomerulopathy, dense deposit disease, ic-mpgn, immune complex membranoproliferative glomerulonephritis